“…Nevertheless, its low aqueous solubility at a level of 0.17 g L −1 may result in the delayed onset of action due to sub-therapeutic plasma drug levels, and may also lead to therapeutic failure [8]. For that purpose, new forms of lamotrigine delivery such as nanoliposomes [9], polymeric nanoparticles [10], multiple-unit beads [11], or co-crystals [12], as well as alternative routes of its administration, such as intrathecal [13], transdermal [14], or nasal [15], have recently become a hot topic of scientific investigations. Recently, the latter administration route has gained particular attention due to the direct delivery of lamotrigine to the brain [15], but it suffers from fast clearance from the nasal cavity due to mucociliary action, susceptibility to enzymes present in the nasal mucosa, low absorption of polar drugs and macromolecules, lower bioavailability in case of cold or allergies interferes, and irritation to the mucosa [16].…”